

<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="https://www.w3.org/1999/xlink">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Avicenna J Med Biotech</journal-id>
      <journal-id journal-id-type="publisher-id">arij002</journal-id>
      <journal-title-group>
        <journal-title>Avicenna Journal of Medical Biotechnology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2008-2835</issn>
      <issn pub-type="epub">2008-4625</issn>
      <publisher>
        <publisher-name>Avicenna Research Institute</publisher-name>
      </publisher>
    </journal-meta>

    <article-meta>
      <article-id pub-id-type="publisher-id">ajmb10334</article-id>
      <article-id pub-id-type="doi"></article-id>
      <article-id pub-id-type="pmid"></article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
             <subject></subject> 
        </subj-group>
        <subj-group>
            <subject></subject>
        </subj-group> 
      </article-categories>
      <title-group>
        <article-title>A study on Association Between &lt;i&gt;CCRΔ32&lt;/i&gt; Mutation and HCV Infection in Iranian Patients</article-title>
      </title-group>
        <contrib-group><contrib contrib-type="author"><name><surname>Bineshian</surname><given-names>Farahnaz</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Hosseini </surname><given-names>Asieh</given-names></name></contrib></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Sharifi</surname><given-names>Zohreh</given-names></name></contrib><aff>Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran</aff></contrib-group><contrib-group><contrib contrib-type="author"><name><surname>Aghaie</surname><given-names>Afsaneh</given-names></name></contrib></contrib-group>
      <pub-date pub-type="ppub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <pub-date pub-type="epub">
        <day></day>
        <month></month>
        <year></year>
      </pub-date>
      <volume>10</volume>
      <issue>4</issue>
      <fpage>261</fpage>
      <lpage>264</lpage>
      <history>
        <date date-type="received">
          <day>19</day>
          <month>7</month>
          <year>2017</year>
        </date>
        <date date-type="accepted">
          <day>2</day>
          <month>10</month>
          <year>2017</year>
        </date>
      </history>
      <abstract>
      <p>
      &lt;p&gt;Background: Mutations in the coding region of the Chemokine Receptor 5 (&lt;em&gt;CCR5&lt;/em&gt;) genes reduce or eliminate &lt;em&gt;CCR5&lt;/em&gt; expression in immune cells and progression of HCV infection. This study aimed to investigate the role of this mutation in HCV infection in Iranian patients in comparison with healthy individuals.&lt;br /&gt;
Methods: 100 HCV infected patients and 100 healthy individuals were randomly selected. The &lt;em&gt;CCR5&amp;Delta;32&lt;/em&gt; genotypes were determined using specific primers and PCR method.&lt;br /&gt;
Results: The agarose gel electrophoresis showed a189-bp fragment from wild type for both alleles of &lt;em&gt;CCR5 &lt;/em&gt;gene. The &lt;em&gt;CCR5-&amp;Delta;32&lt;/em&gt; allele was not found in any HCV infected and healthy subjects.&lt;br /&gt;
Conclusion: The mutation in &lt;em&gt;CCR5&lt;/em&gt; gene was not detected in any of the two groups; therefore, the role of&lt;em&gt; CCR5&lt;/em&gt; gene expression in immune cells and progression of HCV infection needs to be studied in larger samples in our country.&lt;/p&gt;

      </p>
      </abstract>
    </article-meta>
  </front>
    
</article>
